Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial.
Yan Biao LiaoCongying XiaYiheng ChengQiao LiXin WeiYuanweixiang OuFei ChenYijian LiQi LiuTianyuan XiongZhengang ZhaoYong PengJiafu WeiYuan FengMao ChenPublished in: Trials (2021)
Chinese Clinical Trial Registry ChiCTR2100042266 . Registered on 17 January 2021.
Keyphrases
- open label
- transcatheter aortic valve implantation
- clinical trial
- double blind
- angiotensin converting enzyme
- phase ii
- phase iii
- end stage renal disease
- ejection fraction
- placebo controlled
- aortic valve replacement
- aortic stenosis
- study protocol
- angiotensin ii
- chronic kidney disease
- aortic valve
- randomized controlled trial
- prognostic factors
- phase ii study
- squamous cell carcinoma
- radiation therapy
- peritoneal dialysis
- coronary artery disease
- cross sectional